Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H14NO.Cl |
Molecular Weight | 138.624 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].C[N+](C)([11CH3])CCO
InChI
InChIKey=SGMZJAMFUVOLNK-ULWFUOSBSA-M
InChI=1S/C5H14NO.ClH/c1-6(2,3)4-5-7;/h7H,4-5H2,1-3H3;1H/q+1;/p-1/i1-1;
Choline C 11 injection was approved to help diagnose recurrent prostate cancer. It is used for a procedure called positron emission tomography (PET) scan to detect tumors that are not detectable by other scanning procedures, such as bone scan, computed tomography (CT), or magnetic resonance imaging (MRI). Choline C 11 is a radioactive diagnostic agent, the analog of choline. Choline is involved in the synthesis of the structural components of cell membranes, as well as modulation of transmembrane signaling. Increased phospholipid synthesis (i.e., increased uptake of choline) has been associated with cell proliferation and the transformation process that occurs in tumor cells. Recently, Choline C 11 PET was studied for diagnosis the patients with hepatocellular carcinoma; although the phase II of clinical trials was not begun.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | CHOLINE C-11 Approved UseCholine C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected
prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration. Launch Date2012 |
|||
Diagnostic | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion. | 2017 Oct |
|
11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. | 2017 Oct 21 |
|
11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer. | 2017 Sep 12 |
|
Contribution of (11)C-Choline PET/CT in prostate carcinoma biochemical relapse with serum PSA level below 1 ng/ml. | 2018 May-Jun |
Sample Use Guides
The recommended dose is 370 to 740 MBq (10 to 20 mCi) administered as a bolus intravenous injection. The radioactivity dose (370 to 740 MBq, 10 to 20 mCi) is chosen based on patient body dimensions and the characteristics of the image acquisition system.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
14989482
Created by
admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
|
PRIMARY | |||
|
DB09277
Created by
admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
|
PRIMARY | |||
|
300000013060
Created by
admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
|
PRIMARY | |||
|
DTXSID50236498
Created by
admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
|
PRIMARY | |||
|
72321
Created by
admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
|
PRIMARY | |||
|
381E0BTR5Q
Created by
admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
|
PRIMARY | |||
|
87591-54-6
Created by
admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD